-
Posted by
Two Blokes Jul 30 -
Filed in
Stock
-
2 views
XBI has rebounded over 20% since lows in April, despite changes at the FDA that could have signaled a tougher regulatory environment. Vinay Prasad was only appointed in May, but is now leaving the FDA, meaning there will again be a new Director of the Center for Biologics Evaluation and Research. Prasad's appointment caused XBI to drop in May, but the sector still continued on with its recovery.
